問題詳情
28.根據 NCCN Guideline for kidney cancer 2020 第一版，針對轉移性 clear cell type renalcell carcinoma，有關第一線治療的「preferred regimen」 ，下列何者未列入其中？
(A) Ipilimumab + Nivolumab for favorable risk group
(B) Axitinib + Pembrolizumab for favorable risk group
(C) Cabozantinib for poor/intermediate risk group
(D) Axitinib + Pembrolizumab for poor/intermediate risk group
(E) Ipilimumab + Nivolumab for poor/intermediate risk group
參考答案
答案：A
難度：計算中-1
書單：沒有書單，新增